Provided herein are fluorinated compounds having chemical structures: (I) where n is 0 or greater, or (II) where m and n are 0 or greater, or an amino acid, a soluble polymer, an oligo(ethylene glycol), a poly(ethylene glycol), or a carbohydrate each fluorinated with perfluorocarbons having the chemical structure (III) where n is 0 or greater. These fluorinated compounds are utilized in contact lenses to impart lipid-resistant, protein-resistant and biofouling-resistant properties, thus reducing discomfort and infection caused by contact lens wear without changing its transmission characteristics. Also provided is an ophthalmic drug delivery system comprising at least one of the compounds described above embedded in the contact lens and a kit to incorporate the ophthalmic into a contact lens. Methods for incorporating these compounds onto a contact lens without affecting transparency and for use in treating an ophthalmologic-associated condition are provided.

The present technology provides a process for selectively preparing an (E)-(2-(chloromethyl)-3-fluoroallyl)carbamate compound by refluxing an (E/Z)-(2-(chloromethyl)-3-fluoroallyl)carbamate compound in an organic solvent, followed by crystallization by cooling.

The present technology provides a process for selectively preparing an (E)-(2-(chloromethyl)-3-fluoroallyl)carbamate compound by refluxing an (E/Z)-(2-(chloromethyl)-3-fluoroallyl)carbamate compound in an organic solvent, followed by crystallization by cooling.

The present technology provides a process for selectively preparing an (E)-(2-(chloromethyl)-3-fluoroallyl)carbamate compound by refluxing an (E/Z)-(2-(chloromethyl)-3-fluoroallyl)carbamate compound in an organic solvent, followed by crystallization by cooling.

The present technology provides a process for selectively preparing an (E)-(2-(chloromethyl)-3-fluoroallyl)carbamate compound by refluxing an (E/Z)-(2-(chloromethyl)-3-fluoroallyl)carbamate compound in an organic solvent, followed by crystallization by cooling.

The present technology provides a process for selectively preparing an (E)-(2-(chloromethyl)-3-fluoroallyl)carbamate compound by refluxing an (E/Z)-(2-(chloromethyl)-3-fluoroallyl)carbamate compound in an organic solvent, followed by crystallization by cooling.

The present technology provides a process for selectively preparing an (E)-(2-(chloromethyl)-3-fluoroallyl)carbamate compound by refluxing an (E/Z)-(2-(chloromethyl)-3-fluoroallyl)carbamate compound in an organic solvent, followed by crystallization by cooling.

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

##STR00001##

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

##STR00001##

The present invention relates to a compound for release agent and method for preparing the same, and more specifically, to a compound for a release agent that can be coated in an ultra-thin form without thermal deformation even when heat is continuously or discontinuously applied in a continuous evaporator, and a method for preparing the same.